Resistant hypertension revisited: Definition and true prevalence

Journal of Hypertension

Volumn 32, Issue 7, 2014, Pages 1546-

  Modolo, Rodrigo ^a   De Faria, Ana P ^a   Sabbatini, Andreéa R ^a   Moreno, Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; VALSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; HUMAN; LETTER; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; COMPLICATION; CORONARY ARTERY DISEASE; FEMALE; HYPERTENSION; MALE;

CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; MALE;

EID: 84903844879     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000219     Document Type: Letter

References (9)

1. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens 2014; 32:635- 643.
2. Pepine CJ, Handberg EM, Cooper-Dehoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290:2805-2816.
3. Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, et al. VALUE trial: Long-termblood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16:544-548.
4. Furberg CD, Wright JT, Davis BR, Cutler JA, Alderman M, Black H, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
5. Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlof B, Poulter NR, Investigators A. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): A risk score to identify those at high-risk. J Hypertens 2011; 29:2004-2013.
6. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA 2003; 289:2073- 2082.
7. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
8. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR, Serv RUH. Resistant hypertension revisited: A comparison of two university-based cohorts. Am J Hypertens 2005; 18:619-626.
9. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: Definition, prevalence, and patient characteristics. J Clin Hypertens 2012; 14:7-12.